TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations

Registry ID

2026-525336-41-00

Source registry

CTIS

Status

Authorised

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

Assistance Publique Hopitaux De Paris

Enrollment

30

Last update

2026-08-14

Conditions

• Diseases [C] - Respiratory Tract Diseases [C08]
• Interstitial Lung Disease

Primary outcomes

Difference in forced vital capacity decline between the 2 groups at one year

Locations

• , , France

Related clinical trials

• Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
• Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
• Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
• An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
• Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
• A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors

View on source registry